Liquidia (NASDAQ:LQDA) Given New $25.00 Price Target at Wells Fargo & Company

Liquidia (NASDAQ:LQDA) had its target price increased by Wells Fargo & Company from $23.00 to $25.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts also recently issued research reports about the company. HC Wainwright boosted their target price on Liquidia from $29.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, May 28th. Raymond James boosted their target price on Liquidia from $27.00 to $29.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 9th. Wall Street Zen raised Liquidia from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Scotiabank upped their price objective on Liquidia from $36.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Wednesday, May 28th. Finally, Bank of America lowered their price objective on Liquidia from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.89.

Liquidia Trading Up 2.3%

Shares of NASDAQ LQDA opened at $14.45 on Thursday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -8.87 and a beta of 0.04. Liquidia has a 12 month low of $8.26 and a 12 month high of $19.41. The stock has a 50-day moving average price of $15.12 and a two-hundred day moving average price of $14.11.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, sell-side analysts predict that Liquidia will post -1.51 earnings per share for the current year.

Insider Activity

In related news, insider Jason Adair sold 1,856 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now directly owns 184,304 shares in the company, valued at $2,501,005.28. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Michael Kaseta sold 8,283 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $112,400.31. Following the completion of the sale, the chief financial officer now owns 396,315 shares in the company, valued at $5,377,994.55. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock valued at $450,233 over the last quarter. 26.50% of the stock is owned by company insiders.

Institutional Trading of Liquidia

Several institutional investors have recently added to or reduced their stakes in the stock. Corebridge Financial Inc. boosted its holdings in Liquidia by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock valued at $371,000 after acquiring an additional 694 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after acquiring an additional 1,173 shares during the last quarter. Cetera Investment Advisers boosted its holdings in Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock valued at $367,000 after acquiring an additional 1,277 shares during the last quarter. Valmark Advisers Inc. boosted its holdings in Liquidia by 7.4% in the first quarter. Valmark Advisers Inc. now owns 18,641 shares of the company’s stock valued at $275,000 after acquiring an additional 1,283 shares during the last quarter. Finally, Bleakley Financial Group LLC boosted its holdings in shares of Liquidia by 6.4% during the 1st quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company’s stock worth $373,000 after buying an additional 1,523 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).